8 clinically reviewed articles, written and peer-reviewed by the HealthRX.com Medical Team.
Showing 8 of 8 clinical reviews.
A detailed examination of enrollment biases, follow-up gaps, generalizability concerns, statistical caveats, and conflict-of-interest disclosures in the STEP-TEENS semaglutide trial for adolescent obesity.
A deep-dive into the STEP-TEENS trial design, randomization, estimand framework, and statistical choices that shaped how semaglutide 2.4 mg performed in adolescents with obesity.
Health-economic analysis of semaglutide 2.4 mg in adolescents from the STEP-TEENS trial: cost per QALY, payer coverage barriers, list-price vs net-price gaps, and value calculations for families weighing treatment initiation.
Analysis of STEP-TEENS follow-up and extension data for semaglutide 2.4 mg in adolescents, including weight regain after treatment cessation, long-term safety signals, and durability of cardiometabolic improvements.
Full breakdown of STEP-TEENS primary and secondary endpoints, confidence intervals, time-course weight loss data, and response distribution for semaglutide 2.4 mg in adolescents with obesity.
A deep-dive into STEP-TEENS pre-specified and post-hoc subgroup analyses by age, sex, BMI, baseline biomarkers, and race/ethnicity, with clinical implications for real-world adolescent prescribing.
A detailed plain-English breakdown of the STEP-TEENS trial, which tested semaglutide 2.4 mg in adolescents with obesity and found 16.1% weight loss versus 0.6% with placebo.
A deep-dive into how the STEP-TEENS trial reshaped adolescent obesity treatment guidelines, prescribing patterns, and real-world clinical decision-making for semaglutide 2.4 mg in teenagers.